Biochemistry

[키워드] 6 hour 6 hours 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition administration age aggravation anti-SARS-CoV-2 antibody ARMS benefit carried clearance rate clinical benefit Clinical deterioration clinical trial clinically Composite conducted convalescent patient Convalescent patients convalescent plasma coronavirus Corticosteroids COVID-19 COVID-19 patients COVID-19 progression COVID-19 symptom CP group criteria death detect Deterioration Donor early stage early stages Efficacy Efficacy and safety Elvira Enrollment evaluate Evidence evidence of except for Final Follow-up groups high risk hospital Hospitalization hospitalized patient hospitalized patients IMPROVE In-hospital death in-hospital mortality in-hospital mortality rate Intervention lack male matter mechanical ventilation Mortality mortality rate Neutralizing antibodies neutralizing antibody not differ observation observations Odds ratio on mechanical ventilation Open-label outcome pandemic participant Patient patients hospitalized patients with COVID-19 performed plasma Plasma transfusion presenting Primary outcome progression proportion Randomized randomized clinical trial randomized patient randomized trial Real-time PCR recruited required researcher respiratory Respiratory failure risk factor Risk factors SARS-CoV-2 secondary outcome Serious Adverse Event Serious Adverse Events severe acute respiratory syndrome Coronavirus single-center small sample size standard treatment Statistical power symptomatic symptomatic COVID-19 Symptoms the patient therapeutic effect therapy Treatment Trial Two patient two patients Viral viral clearance rate virus with COVID-19
[DOI] 10.1371/journal.pmed.1003415 PMC 바로가기 [Article Type] Clinical Trial